UB405
TargetsBTK/LYN
IndicationsChronic lymphocytic leukaemia; Small lymphocytic lymphoma; Diffuse large B-cell lymphoma
ClinicalCN - Pre-PCC
TherapeuticsOncology
ModalitiesSmall Molecule
Exclusive Summary
- • Reversible non-covalent dual BTK/ LYN inhibitors target both BTK-dependent and BTK- independent B-cell receptor (BCR) signaling pathways.
- • Potential to treat resistance mutations of BTK degraders.
- • Better in vivo efficacy in DLBCL than LOXO-305
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →